Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 19(T2)28z1xx TRAC CAR-T cells |
Synonyms | |
Therapy Description |
19(T2)28z1xx TRAC CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and also containing mutated immunoreceptor tyrosine-based activation motifs, which potentially leads to antitumor activity (Blood (2020) 136 (Supplement 1): 43-44). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
19(T2)28z1xx TRAC CAR-T cells | CD19 Immune Cell Therapy 62 | 19(T2)28z1xx TRAC CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and also containing mutated immunoreceptor tyrosine-based activation motifs, which potentially leads to antitumor activity (Blood (2020) 136 (Supplement 1): 43-44). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05757700 | Phase I | 19(T2)28z1xx TRAC CAR-T cells | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma | Recruiting | USA | 0 |